Merck, based in Kenilworth, has announced the halting of the development of the COVID-19 vaccine candidates, V590 and V591.
The decision follows the investigation into the findings of Phase 1 clinical trials for the vaccines.
In the studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen after natural infection and those reported for other SARS-CoV-2 / COVID-19 vaccines.
The company now plans to focus its COVID-19 research strategy and production capability on the promotion of two therapeutic candidates, MK-4482 and MK-7110.
For more information, click here.